BIOMARKERS FOR PROSTATE CANCER

摘要

The disclosure provides methods of using biomarkers to improve diagnosis of forms of prostate. The method includes testing a biological sample from an individual for a interleukin-8 (IL-8), Tumor necrosis factor alpha (TNF-a) and soluble tumor necrosis factor-α receptor 1 (sTNFR1), and may further include testing for prostate serum antigen (PSA). Use of these markers in combination provides tests that are more sensitive and specific than PSA in differentiating benign versus malignant prostate disease and/or localized CaP versus metastatic CaP and show that the specificity and sensitivity of a PSA-based CaP diagnosis can be significantly enhanced by measuring IL-8, TNF-a and sTNFR1.

主权项

1. A method for aiding in distinguishing between metastatic or localized prostate cancer, and for distinguishing between localized prostate cancer and benign prostate disease comprising:
i) in an individual known or suspected to have either the metastatic or the localized prostate cancer, testing a biological sample from the individual to determine interleukin-8 (IL-8), Tumor necrosis factor alpha (TNF-α) and soluble tumor necrosis factor-α receptor 1 (sTNFR1) in the sample, wherein determining IL8 to be equal to or greater than 5.1 pg/ml, TNFa to be equal to or greater than 3.1 pg/ml and sTFNr1 to be equal to or greater than 513.9 pg/ml aids in a diagnosis that the individual has the metastatic disease; or ii) in an individual known or suspected to have the localized prostate cancer or the benign prostate disease, testing a biological sample from the individual to determine the IL-8, TNF-α and the sTNFR1, wherein determining an amount of TNFa of equal to or greater than 1.2 pg/ml and sTFNr1 in an amount equal to or greater than 729 pg/ml aids in a diagnosis that the individual has the localized prostate cancer.